NCT02685137View on ClinicalTrials.gov

Efficacy and Safety of Stannsoporfin in Neonates

PHASE3CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

May 1, 2002

Primary Completion Date

March 16, 2003

Study Completion Date

February 28, 2013

Conditions
Nutritional and Metabolic Diseases
Interventions
DRUG

stannsoporfin

Intramuscular injection of stannsoporfin to treat jaundice.

OTHER

Sham Injection

nothing

Trial Locations (1)

19107

Pennsylvania Hospital, Philadelphia

All Listed Sponsors
lead

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

INDUSTRY

NCT02685137 - Efficacy and Safety of Stannsoporfin in Neonates | Biotech Hunter | Biotech Hunter